Tag - David Platt

By Len Zehr Boston Therapeutics (OTCQB:BTHE) hopes to begin a pivotal Phase 3 trial, by the second or third quarter of 2014, of a chewable tablet that is designed to be taken before meals to reduce post-meal elevation...